What is the current Price Target for the BB Biotech stock?

The average BB Biotech target price is CHF57.05. This is 54.80% higher than the current stock price. The highest price target is 73.68%, the lowest is 29.44%. 3 Analysts have issued a price target BB Biotech 2025 .

How high will the BB Biotech stock rise?

No reliable answer can be given as to how high the BB Biotech stock will rise. The performance of stocks, including the BB Biotech stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the BB Biotech stock today?

The performance of BB Biotech stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the BB Biotech stock fall?

The decline in BB Biotech stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

BB Biotech Forecast, price target & analysts

CHF36.85

0.41% day before yesterday

SIX Swiss Exchange, Sep 27, 05:30 pm CET

ISIN

CH0038389992

Symbol

BION

Sector

Finances

Industry

Financial service provider

Overview Dividends Analysts Charts News Strategies

BB Biotech Target price 2024 - Analyst rating & recommendation

BB Biotech Classifications & Recommendation:

Buy

100%

BB Biotech Price Target

Target Price	CHF57.05
Price	CHF36.85
Potential	54.80% register free of charge
Number of Estimates	3

	3 Analysts have issued a price target BB Biotech 2025 . The average BB Biotech target price is CHF57.05. This is 54.80% register free of charge higher than the current stock price. The highest price target is CHF64.00 73.68% register free of charge , the lowest is CHF47.70 29.44% register free of charge .
	A rating was issued by 3 analysts: 3 Analysts recommend BB Biotech to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the BB Biotech stock has an average upside potential 2025 of 54.80% register free of charge . Most analysts recommend the BB Biotech stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '23	2024 Estimates
Earnings Per Share CHF	-3.77	3.73
	42.00%	198.94%
P/E		9.89

2 Analysts have issued a BB Biotech forecast for earnings per share. The average BB Biotech <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2023	CHF-3.77	42.00%
2024	CHF3.73 198.94% Unlock
2025	CHF3.05 18.23% Unlock
2026	CHF3.58 17.38% Unlock

Current	8.63	134.26%
2024	9.89 14.60% Unlock
2025	12.08 22.14% Unlock
2026	10.31 14.65% Unlock

BB Biotech...

Discover more stocks with a high price target

Valneva 193.41%

CureVac N.V. 166.83%

Evotec 97.18%

Plug Power Inc. 78.07%

Bavarian Nordic 35.24%

Volkswagen VZ 35.11%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now